--- title: "Innovative pharmaceutical companies' overseas licensing collaborations remain active, and the Hong Kong Connect Innovative Drugs ETF Harvest (520970) is expected to continue benefiting" type: "News" locale: "en" url: "https://longbridge.com/en/news/281299813.md" description: "The overseas licensing cooperation of innovative pharmaceutical companies continues to be active, and the Harvest CSI Hong Kong Connect Innovative Drugs ETF (520970) is expected to benefit continuously. On the morning of April 1, 2026, the CSI Hong Kong Connect Innovative Drugs Index rose by 4.91%, with constituent stock LEPU BIO-B increasing by 11.24%. In the first three months of 2026, the total value of foreign licensing transactions for innovative drugs in China has exceeded USD 60 billion. The NMPA has launched the \"Spring Rain Action\" for the transformation of clinical innovation achievements in medical devices, supporting the industrialization of innovative results. The valuation of the pharmaceutical sector is 29.3 times PE, lower than the historical average, and the market's attention to innovative pharmaceutical companies with core technology platforms has increased" datetime: "2026-04-01T02:59:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281299813.md) - [en](https://longbridge.com/en/news/281299813.md) - [zh-HK](https://longbridge.com/zh-HK/news/281299813.md) --- # Innovative pharmaceutical companies' overseas licensing collaborations remain active, and the Hong Kong Connect Innovative Drugs ETF Harvest (520970) is expected to continue benefiting On April 1, 2026, in the morning session, as of 10:22, the CSI Hong Kong Connect Innovative Drug Index surged by 4.91%. Component stocks such as LEPU BIO-B rose by 11.24%, Rongchang Bio increased by 8.46%, and Kelaiying climbed by 8.02%, with Junshi Bioscience, Zhaoyan New Drug, and other stocks also following suit. In terms of news, recently, overseas licensing cooperation among innovative drug companies has remained active. In the first three months of 2026, the total value of China's innovative drug licensing transactions exceeded USD 60 billion, approaching half of the total for the entire year of 2025. The participation and recognition of Chinese innovative drug assets in the global trading system continue to rise. Meanwhile, the NMPA has launched a three-year "Spring Rain Action" for the clinical innovation results transformation of medical devices, further strengthening support for the industrialization of innovative results. Additionally, with the upcoming 2026 AACR Annual Meeting, Chinese companies are expected to intensively disclose global clinical progress in ADCs, bispecific antibodies, small molecules, and CAR-T, providing important data catalysts for the innovative drug sector. Furthermore, the trend of dual-driven commercialization and R&D among domestic innovative drug companies is clear, and the industry as a whole maintains a "recommended" rating. As of March 27, 2026, the valuation of the pharmaceutical sector was 29.3 times PE (TTM), below the historical average of 34.9 times PE, with a relative premium rate of only 10.99% compared to all A-shares (excluding finance), which is at a historically low to medium level. Currently, market attention is continuously increasing for innovative drug companies with core technology platforms, differentiated pipeline layouts, and global cooperation potential. The logic of innovative drugs and devices has not fundamentally changed, and companies' independent R&D capabilities are accelerating to deliver results. Data shows that as of March 31, 2026, the top ten weighted stocks in the CSI Hong Kong Connect Innovative Drug Index were WuXi Biologics, Innovent Biologics, BeiGene, CanSino Biologics, CSPC Pharmaceutical Group, China National Pharmaceutical Group, Hansoh Pharmaceutical, WuXi AppTec, 3SBio, and Crystal Digital Holdings, with the top ten weighted stocks accounting for a total of 71.57%. The Hong Kong Connect Innovative Drug ETF, Harvest (520970), closely tracks the CSI Hong Kong Connect Innovative Drug Index, with index component stocks involving innovative drug R&D and providing services such as drug research, development, and production for pharmaceutical companies, encompassing leading innovative drug stocks in Hong Kong. Investors without stock accounts can seize opportunities in the Hong Kong innovative drug industry through the Hong Kong Connect Innovative Drug ETF feeder fund (024700) ### Related Stocks - [02157.HK](https://longbridge.com/en/quote/02157.HK.md) - [520700.CN](https://longbridge.com/en/quote/520700.CN.md) - [520970.CN](https://longbridge.com/en/quote/520970.CN.md) - [513780.CN](https://longbridge.com/en/quote/513780.CN.md) ## Related News & Research - [Universal Digital Inc. Announces Termination of ETF Partnership Agreement | LFGMF Stock News](https://longbridge.com/en/news/286616540.md) - [Keep Your Portfolio Safe With This Low-Volatility ETF](https://longbridge.com/en/news/286604877.md) - [1 Rapidly Deteriorating ETF Screams That ‘Shop ‘Til You Drop’ Americans Have All But Keeled Over](https://longbridge.com/en/news/286429552.md) - [BNB ETF Could Be Next Big Crypto Breakthrough, Says Bloomberg Analyst](https://longbridge.com/en/news/286639724.md) - [VanEck, Grayscale file fresh BNB ETF amendments as race for next altcoin spot ETF accelerates](https://longbridge.com/en/news/286652991.md)